Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?

Ann Oncol. 2018 Nov 1;29(11):2160-2162. doi: 10.1093/annonc/mdy415.

Authors

A A Thai¹, B J Solomon²

Affiliations

¹ Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne.
² Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia. Electronic address: ben.solomon@petermac.org.

PMID: 30239586
DOI: 10.1093/annonc/mdy415

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anaplastic Lymphoma Kinase
Carbazoles
Carcinoma, Non-Small-Cell Lung*
Crizotinib
Humans
Lung Neoplasms*
Piperidines

Substances

Carbazoles
Piperidines
Crizotinib
Anaplastic Lymphoma Kinase
alectinib